Purchase this article with an account.
Arthur Driscoll, Charles D Blizzard, Ankita Desai, Jennifer Langh, Noah Buff, Jamie L Metzinger, Michael H Goldstein, Ann Gelormini; Effect of OTX-TIC, a Sustained Release Travoprost Intracameral Implant on Central Corneal Thickness in Beagles. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3345. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effect of a travoprost sustained release intracameral hydrogel implant, OTX-TIC on central corneal thickness (CCT) in beagles. OTX-TIC is a potential new therapy to treat glaucoma.
Two studies were performed in beagle dogs. In the first study, OTX-TIC was injected bilaterally (OU) into the anterior chamber (AC) of 6 beagles through a 27 G needle. CCT was measured at baseline and post-administration at 0.5 months and then monthly through 7 months using an ultrasonic pachymeter (Sonomed). In the second study, OTX-TIC (n=16 eyes, OU) or vehicle implant (no drug, n=8 eyes, OS) was injected similarly and compared to untreated eyes (n=8 eyes, OD). CCT was measured at baseline and post-administration at 30, 60, 90 and 120 days using an iPac pachymeter (Reichert).
OTX-TIC, currently in Phase 1 clinical trials, is designed to reside in the inferior iridocorneal angle within the AC providing sustained release of travoprost over 4 months in beagles with longer release durations projected in humans. Results in beagles following OTX-TIC administration into the AC demonstrated no reduction in CCT either over 7 months in study 1 or over 4 months in study 2 compared to baseline values or when compared to either vehicle control or untreated eyes in beagles
CCT monitoring is important in evaluating intracameral inserts because increased corneal thickness may be indicative of damage to the corneal endothelium. Both of these studies showed no change in corneal thickness over the course of the study periods (7 months and 4 months). As OTX-TIC resides in the inferior iridocorneal angle, it principally releases low levels of the active form of travoprost (free acid) into the AH proximate to the targeted tissues demonstrating potential as a sustained release glaucoma treatment.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
Central corneal thickness pre- and post-OTX-TIC administration in 24 beagle eyes over 7 months
Central corneal thickness pre- and post-OTX-TIC administration compared to vehicle control and untreated beagle eyes over 4 months
This PDF is available to Subscribers Only